Organisation paid for research Program year 2024 Source: CMS Open Payments

Center for Biomedical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$242,159

97 payments

Through program year 2024, Center for Biomedical Research, LLC is reported as receiving $242,159 in research payments, across 97 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $91,407 43
2023 Research $49,517 8
2022 Research $22,053 7
2021 Research $1,706 1
2020 Research $21,326 19
2019 Research $56,150 19

Breakdown

Who paid Research payments · program years 2019–2024
  1. United Therapeutics Corporation $116,950 41 payments
  2. EMD Serono, Inc. $56,150 19 payments
  3. Merck Healthcare KGaA $45,341 23 payments
  4. BeiGene, Ltd. $23,718 14 payments
Studies the money was for Research payments · program years 2019–2024
  1. Emr 200647-001 $56,150 19 payments
  2. Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (Phinder) $54,837 11 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to Pah Standard of Care Or Pah-Specific Background Oral Therapy in Subjects With Who Group I Pulmonary Hypertension $40,787 11 payments
  4. An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies $24,427 19 payments
  5. AdvanTIG-205 $23,718 14 payments
  6. An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies $20,039 3 payments
  7. A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients $16,551 14 payments
  8. A Two-Part Open-Label Randomized Phase II/III Study of Dinutuximab and Irinotecan Versus Irinotecan for Second-Line Treatment of Subjects With Relapsed Or Refractory Small Cell Lung Cancer $3,560 3 payments
  9. A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension $1,215 2 payments
  10. An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies $875 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record